Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).
Saved in:
| Title: | Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003). |
|---|---|
| Authors: | Kim JS; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Blood Cancer Research Institute, Seoul, Republic of Korea., Song Y; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Jen WY; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Chim CS; Comprehensive Oncology Centre, 3/F, Li Shu Fan Block, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China., Lee JJ; Chonnam National University Hwasun Hospital, Hwasun, Republic of South Korea., Yoon SS; Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Ng SC; Subang Jaya Medical Center, Petaling Jaya, Malaysia., Gan GG; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Handa H; Department of Hematology, Gunma University Hospital, Maebashi, Gunma, Japan., Lee JH; Gachon University Gil Medical Center, Incheon, Republic of South Korea., Kim K; Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Republic of South Korea., Ito S; Department of Hematology & Oncology, Iwate Medical University Hospital, Yahaba, Japan., Huang JS; National Taiwan University, Taipei, Taiwan., Min CK; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Ooi Gaik Ming M; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., de Mel S; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Soekojo C; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Li X; Singapore Clinical Research Institute, Singapore, Singapore., Awasthi N; Singapore Clinical Research Institute, Singapore, Singapore., Pokharkar Y; Singapore Clinical Research Institute, Singapore, Singapore., Durie BG; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA., Chng WJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Oct 06; Vol. 15 (1), pp. 155. Date of Electronic Publication: 2025 Oct 06. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41052983 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kim+JS%22">Kim JS</searchLink>; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Blood Cancer Research Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Song+Y%22">Song Y</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Jen+WY%22">Jen WY</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Chim+CS%22">Chim CS</searchLink>; Comprehensive Oncology Centre, 3/F, Li Shu Fan Block, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Lee+JJ%22">Lee JJ</searchLink>; Chonnam National University Hwasun Hospital, Hwasun, Republic of South Korea.<br /><searchLink fieldCode="AU" term="%22Yoon+SS%22">Yoon SS</searchLink>; Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ng+SC%22">Ng SC</searchLink>; Subang Jaya Medical Center, Petaling Jaya, Malaysia.<br /><searchLink fieldCode="AU" term="%22Gan+GG%22">Gan GG</searchLink>; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.<br /><searchLink fieldCode="AU" term="%22Handa+H%22">Handa H</searchLink>; Department of Hematology, Gunma University Hospital, Maebashi, Gunma, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+JH%22">Lee JH</searchLink>; Gachon University Gil Medical Center, Incheon, Republic of South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+K%22">Kim K</searchLink>; Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Republic of South Korea.<br /><searchLink fieldCode="AU" term="%22Ito+S%22">Ito S</searchLink>; Department of Hematology & Oncology, Iwate Medical University Hospital, Yahaba, Japan.<br /><searchLink fieldCode="AU" term="%22Huang+JS%22">Huang JS</searchLink>; National Taiwan University, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Min+CK%22">Min CK</searchLink>; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Ooi+Gaik+Ming+M%22">Ooi Gaik Ming M</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22de+Mel+S%22">de Mel S</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Soekojo+C%22">Soekojo C</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Awasthi+N%22">Awasthi N</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Pokharkar+Y%22">Pokharkar Y</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Durie+BG%22">Durie BG</searchLink>; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chng+WJ%22">Chng WJ</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2025 Oct 06; Vol. 15 (1), pp. 155. <i>Date of Electronic Publication: </i>2025 Oct 06. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41052983 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-025-01356-z Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 155 Titles: – TitleFull: Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kim JS – PersonEntity: Name: NameFull: Song Y – PersonEntity: Name: NameFull: Jen WY – PersonEntity: Name: NameFull: Chim CS – PersonEntity: Name: NameFull: Lee JJ – PersonEntity: Name: NameFull: Yoon SS – PersonEntity: Name: NameFull: Ng SC – PersonEntity: Name: NameFull: Gan GG – PersonEntity: Name: NameFull: Handa H – PersonEntity: Name: NameFull: Lee JH – PersonEntity: Name: NameFull: Kim K – PersonEntity: Name: NameFull: Ito S – PersonEntity: Name: NameFull: Huang JS – PersonEntity: Name: NameFull: Min CK – PersonEntity: Name: NameFull: Ooi Gaik Ming M – PersonEntity: Name: NameFull: de Mel S – PersonEntity: Name: NameFull: Soekojo C – PersonEntity: Name: NameFull: Li X – PersonEntity: Name: NameFull: Awasthi N – PersonEntity: Name: NameFull: Pokharkar Y – PersonEntity: Name: NameFull: Durie BG – PersonEntity: Name: NameFull: Chng WJ IsPartOfRelationships: – BibEntity: Dates: – D: 06 M: 10 Text: 2025 Oct 06 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2044-5385 Numbering: – Type: volume Value: 15 – Type: issue Value: 1 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |
